Engineering CAR-T Cells for Improved Function Against Solid Tumors

Genetic engineering T cells to create clinically applied chimeric antigen receptor (CAR) T cells has led to improved patient outcomes for some forms of hematopoietic malignancies. While this has inspired the biomedical community to develop similar strategies to treat solid tumor patients, challenges...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Michael A., Schambach, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217729/
https://www.ncbi.nlm.nih.gov/pubmed/30420856
http://dx.doi.org/10.3389/fimmu.2018.02493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217729/
https://www.ncbi.nlm.nih.gov/pubmed/30420856
http://dx.doi.org/10.3389/fimmu.2018.02493

Ejemplares similares